Antharis Therapeutics, Inc

Antharis Therapeutics is a multinational biopharmaceutical company developing new treatments for cancer and inflammatory diseases. In particular, our company utilizes cutting-edge science to develop therapeutic monoclonal antibodies and antibody-drug conjugates with the end goal of treating unmet medical needs. The company, founded by Dr. Raphael R Pinaud in 2020, has significantly grown and successfully advanced its mission to date. Furthermore, Antharis strategically acquired Cassyni Biopharma and Galileo Biotech, in mid-2022 and mid-2023, respectively, to further and more effectively advance its mandate to bring transformational therapies to patients in need

Antibodies,therapies,antibody drug conjugates,therapeutic antibodies,monoclonal antibodies,neurology,neuroscience,neurological disorders,alzheimer's disease,parkinson's disease,multiple sclerosis,cancer,oncology,cancer biology,biotechnology,biotech,pharmaceutical,and biopharma

Antharis therapeutics, inc operates in the Biotechnology industry.

Antharis therapeutics, inc's revenue is 11m - 100m

Antharis therapeutics, inc has 11 - 50 employees.